Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement

Authors


Moises A. Calderon, Section of Allergy and Clinical Immunology, Imperial College, National Heart and Lung Institute, Royal Brompton Hospital, Dovehouse Street, London SW3 6LY, UK.
Tel.: 00 44 20 7351 8024
Fax: 00 44 20 7349 7768
E-mail: m.calderon@imperial.ac.uk

Abstract

To cite this article: Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, Eng P, Niggemann B, Nieto A, Valovirta E, Eigenmann PA, Pajno G, Bufe A, Halken S, Beyer K, Wahn U. Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement. Pediatr Allergy Immunol 2012: 23: 300–306.

Abstract

This article is the result of consensus reached by a working group of clinical experts in paediatric allergology as well as representatives from an ethical committee and the European Medicine Agency (EMA). The manuscript covers clinical, scientific, regulatory and ethical perspectives on allergen-specific immunotherapy in childhood. Unmet needs are identified. To fill the gaps and to bridge the different points of view, recommendations are made to researchers, to scientific and patient organizations and to regulators and ethical committees. Working together for the benefit of the community is essential. The European Academy of Allergy and Clinical Immunology (EAACI) serves as the platform of such cooperation.

Ancillary